Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives Average Rating of "Moderate Buy" from Analysts

Key Points

• Analysts give Kiniksa a consensus rating of Moderate Buy (7 buys, 1 hold, 1 sell) with an average 12‑month target of $56.00, and recent firm notes range roughly from $50 to $62 amid both upgrades and downgrades.
• Company insiders, including the CEO and COO, sold shares under Rule 10b5‑1 plans — a total of 61,479 shares (~$2.83M) in the last 90 days — even though insiders still own about 53% of the stock.
• In the latest quarter Kiniksa missed EPS estimates ($0.17 vs. $0.29) but revenue rose to $202.1M, up 65% year‑over‑year; the stock has a market cap of $3.34B and a P/E around 59.

Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the nine analysts that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $56.00.

A number of analysts have recently issued reports on KNSA shares. Canaccord Genuity Group assumed coverage on Kiniksa Pharmaceuticals International in a report on Thursday, February 19th. They set a "buy" rating and a $62.00 target price for the company. Wells Fargo & Company boosted their price target on Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 25th. Wall Street Zen lowered Kiniksa Pharmaceuticals International from a "buy" rating to a "hold" rating in a research report on Sunday. Zacks Research lowered Kiniksa Pharmaceuticals International from a "hold" rating to a "strong sell" rating in a research report on Friday, April 17th. Finally, Wedbush boosted their price target on Kiniksa Pharmaceuticals International from $53.00 to $58.00 and gave the stock an "outperform" rating in a research report on Thursday, April 16th.

Insider Activity

In related news, COO Ross Moat sold 2,367 shares of the business's stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $48.58, for a total transaction of $114,988.86. Following the transaction, the chief operating officer directly owned 12,029 shares of the company's stock, valued at approximately $584,368.82. The trade was a 16.44% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Sanj K. Patel sold 7,278 shares of the business's stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $50.01, for a total value of $363,972.78. Following the transaction, the chief executive officer directly owned 7,278 shares in the company, valued at $363,972.78. This trade represents a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 61,479 shares of company stock worth $2,832,812 in the last ninety days. 53.48% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

Hedge funds and other institutional investors have recently bought and sold shares of the stock. EverSource Wealth Advisors LLC raised its position in shares of Kiniksa Pharmaceuticals International by 140.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company's stock valued at $25,000 after purchasing an additional 532 shares in the last quarter. Osaic Holdings Inc. acquired a new position in shares of Kiniksa Pharmaceuticals International in the 2nd quarter valued at approximately $31,000. Smartleaf Asset Management LLC acquired a new position in shares of Kiniksa Pharmaceuticals International in the 4th quarter valued at approximately $36,000. Nano Cap New Millennium Growth Fund L P acquired a new position in shares of Kiniksa Pharmaceuticals International in the 4th quarter valued at approximately $41,000. Finally, CIBC Private Wealth Group LLC acquired a new position in shares of Kiniksa Pharmaceuticals International in the 4th quarter valued at approximately $41,000. 53.95% of the stock is owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals International Stock Performance

Shares of NASDAQ:KNSA opened at $43.61 on Tuesday. Kiniksa Pharmaceuticals International has a 1 year low of $21.25 and a 1 year high of $50.03. The stock has a market capitalization of $3.34 billion, a P/E ratio of 58.93 and a beta of 0.06. The stock has a 50-day simple moving average of $45.94 and a 200-day simple moving average of $42.86.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last issued its earnings results on Tuesday, February 24th. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.29 by ($0.12). Kiniksa Pharmaceuticals International had a return on equity of 11.48% and a net margin of 8.71%.The firm had revenue of $202.13 million for the quarter, compared to analysts' expectations of $200.86 million. During the same quarter in the previous year, the firm posted ($0.12) EPS. The firm's revenue for the quarter was up 65.0% compared to the same quarter last year. Analysts predict that Kiniksa Pharmaceuticals International will post 1.09 earnings per share for the current year.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company's core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company's lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still's disease and Schnitzler syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.